Adimmune Corporation announced the marketing authorization of the Company's quadrivalent influenza vaccine is granted by China's National Medical Products Administration. Upon receiving the marketing authorization from China's National Medical Products Administration, the Company will initiate the marketing of quadrivalent influenza vaccine for adults.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.05 TWD | 0.00% | -1.10% | -18.40% |
1st Jan change | Capi. | |
---|---|---|
-18.40% | 350M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 4142 Stock
- News Adimmune Corporation
- Adimmune Corporation Announces the Approval of the Company's Quadrivalent Influenza Vaccine from China's National Medical Products Administration